A 41-year-old man, complaining of leg cramps, was found to have persistent hyperkalemia. Except for mild hypertension, his physical examination and laboratory values to exclude connective tissue diseases and diabetes mellitus were normal. Renal function testing revealed a normal glomerular filtration rate and tubular capacity to acidify and dilute, as well as near-normal ability to concentrate his urine. Hormonal evaluation revealed a normal cortisol, as well as normal resting and stimulated renin and aldosterone levels. A selective defect in tubular potassium secretion was demonstrated. In the absence of aldosterone deficiency or renal dysfunction, it was assumed that the patient had primary renal resistance to aldosterone, known as pseudohypoaldosteronism. Treatment with hydrochlorothiazide controlled his hyperkalemia and hypertension. His case emphasizes the diagnostic and therapeutic factors that should be considered in evaluating and treating a non-hospitalized patient with sustained hyperkalemia.
INTRODUCTION
A 41-year-old white man was referred to nephrology clinic for evaluation of hyperkalemia, discovered in 1983 when serum potassium levels of 5.5 and 5.4 mEq/l were noted during an evaluation for intermittent muscle ache. His only other medical problem was mild hypertension, controlled with clonidine. He took no other medications, and his only complaint was of leg cramps after heavy exertion, which had started one year previously. His family history was significant for a son and daughter with confirmed hyperkalemia, and a sister reported to have "high potassium." There was no family history of paralysis or muscle weakness. His physical exam was completely normal, including a blood pressure (BP) of 130/82. An intravenous pyelogram was normal, with no evidence of obstruction or urinary reflux. Evaluation for connective tissue diseases, systemic lupus erythematosus (SLE), and neurologic diseases, with serologies and an electromyogram (EMG), was negative. Pertinent lab values are presented in Table 1 .
Historical chemistry values demonstrated chronic hyperkalemia with normal serum bicarbonate values and normal serum creatinine concentration. White blood cell and platelet counts were normal, and plasma potassium measurements confirmed hyperkalemia. As shown in Table 1 , his glomerular filtration rate, as reflected by his serum creatinine level, and his renal tubular ability to lower urine pH and Errors in measurement were eliminated through measuring plasma K+ and measuring white blood cell and platelet counts. To exclude selective hypoaldosteronism, another relatively common cause of chronic hyperkalemia, it is necessary to demonstrate normal adrenal responsiveness to maneuvers which stimulate aldosterone production, such as ACTH infusion, upright posture, volume contraction, and potassium infusion. Our patient responded normally to upright posture and volume contraction by increasing his serum aldosterone (Table 1) . This ability to augment his aldosterone production when stimulated, coupled with a lack of evidence for any of the other causes for hyperkalemia, suggests that his defect is resistance to the action of aldosterone, either a selective tubular defect or a more generalized cellular defect in potassium uptake. The former clinical entity has been called pseudohypoaldosteronism [4, 5] , and the next part of this discussion will deal with its clinical manifestations.
The early descriptions of pseudohypoaldosteronism were in infants [6, 7] , characterized by failure to thrive, metabolic acidosis, hyperkalemia, and mineralocorticoidresistant urinary sodium wasting. Plasma renin and aldosterone were both elevated, and there were no other adrenal enzyme abnormalities. The congenital defect is related to a lack or deficiency of aldosterone receptors in some cases [8, 9] and can be inherited [10] [11] [12] [13] . In addition, children have been reported with abnormally high urinary excretion of the prostaglandins PGE2 and PGF2a [14] , which may be second-ary to the basic defect in pseudohypoaldosteronism. Children with pseudohypoaldosteronism respond normally to infusion of ACTH or potassium with increases in urinary and serum aldosterone [12] , suggesting an intact normal adrenal responsiveness. The children usually respond to large amounts of dietary sodium chloride replacement with resumption of normal growth and often eventually recover normal renal handling of sodium and potassium. This group has been classified as pseudohypoaldosteronism type I by Schambelan et al. [5] . It is the most common form of pseudohypoaldosteronism, as judged by the number of cases reported in the literature [8, 9, 12, [14] [15] [16] [17] [18] [19] [20] [21] .
More recently, a group of adult patients has been described with features similar to those of the children described above [4, 5, 13, [22] [23] [24] [25] [26] [27] [28] [29] . These patients also have a combination of hyperkalemia and metabolic acidosis. Their renin-angiotensinaldosterone responds normally to maneuvers such as volume contraction or ACTH infusion. The clinical feature that serves to distinguish them from the children above is their lack of salt wasting [5] . Most of these patients, in fact, are hypertensive. The patients vary in their response to the diagnostic and therapeutic interventions, but with one exception [23] all of the published cases have demonstrated metabolic acidosis. This acidosis is a type IV renal tubular acidosis, related to impaired renal ammonia generation. (It is interesting to note that our patient exhibited no acidosis in five years of laboratory testing.) Characteristically their hypertension is described as severe, with systolic blood pressures between 190 and 210 mm Hg, and their serum potassium ranges between 5.3 mEq/l and 8.2 mEq/l. This group of patients is now classified as pseudohypoaldosteronism type II. In distinction to the children described above, there is little long-term follow-up available for these patients, and whether they regain normal renal handling of potassium with time is not known.
In order to diagnose pseudohypoaldosteronism, it is important first to exclude the more common causes of hyperkalemia listed in Table 2 . The next step is to verify normal aldosterone secretion in response to renin stimulation. The third step in the diagnosis is to verify renal resistance to the effects of mineralocorticoids through the administration of fludrocortisone or deoxycorticosterone (DOCA) for several weeks.
The patient with pseudohypoaldosteronism will demonstrate sustained hyperkalemia resistant to the kaliuretic effects of mineralocorticoids. This test must be carefully supervised, since mineralocorticoids can worsen congestive heart failure by stimulating salt and water retention. Figure 1 shows the course of a typical patient with pseudohypoaldosteronism typeII during treatment with oral mineralocorticoid therapy [5] . Urinary and serum potassium remain unchanged, despite increased urinary sodium reabsorption immediately after starting fludrocortisone and again after the addition of DOCA. An important note is that large doses of fludrocortisone (0.5-1.0 mg per day) must be used to document resistance to mineralocorticoid action. It is also important that the patient's intake of potassium remain constant during the test period.
Finally, the patient with pseudohypoaldosteronism type I is distinguished from one with type II by putting the patient on a sodium-restricted diet. Normal ability to conserve sodium (urinary sodium <10 mEq/l) will classify the patient as having pseudohypoaldosteronism typeII [5] .
It has been proposed that the defect in pseudohypoaldosteronism type II is increased chloride reabsorption in the distal tubule [4, 5, 30] . This "chloride shunt" could impair potassium secretion by making the potential difference in the distal tubule less negative, decreasing one of the major driving forces for potassium secretion. Evidence for this hypothesis comes from studies comparing the response to sodium chloride versus sodium sulfate infusion in patients with pseudohypoaldosteronism type II. Figure 2 shows the result of infusion of sodium chloride or sodium sulfate in two such patients, demonstrating their failure to increase potassium excretion during sodium chloride infusion compared with normal controls. In contrast, infusion with sodium sulfate increased urinary potassium excretion in both the patient and the controls. Sulfate and bicarbonate are anions that normally . Potassium excretion increased with both maneuvers in controls, whereas the patient with pseudohypoaldosteronism was resistant to the kaliuretic effect of NaCl due to "chloride shunting." Reprinted with permission [5] . augment potassium excretion, perhaps by making the potential difference more negative in the lumen of the distal tubule. Patients with pseudohypoaldosteronism will increase their potassium excretion during an infusion of either sodium sulfate or sodium bicarbonate, although some patients will have a lower potassium excretion than controls [22, 30] . In contrast, sodium chloride, which normally increases potassium secretion by increasing solute delivery to the distal tubule, fails to increase potassium secretion in these patients, since the "chloride shunt" prevents any change in the potential difference in the distal tubule. More patients with pseudohypoaldosteronism type II need to be evaluated in this manner to determine whether a "chloride shunt" really is the mechanism in this disorder.
Although our patient was not tested with mineralocorticoids to document resistance to their effects, his impaired potassium secretion and low TFKG, in the setting of a normal serum aldosterone level, suggest pseudohypoaldosteronism. Furthermore, his clinical course is consistent with pseudohyopoaldosteronism type II, given his absence of clinical signs of salt wasting. In fact, his hypertension responded to diuretic therapy, suggesting sodium retention as part of its mechanism. Treatment of pseudohypoaldosteronism depends on the severity of the hyperkalemia, as well as other associated medical problems such as acidosis and hypertension. For most patients, use of a low-potassium diet coupled with a mild diuretic should control their hypertension and correct their hyperkalemia. Our observation is that thiazide diuretics are very effective in increasing potassium excretion, perhaps through their ability to increase sodium delivery to the distal tubule, allowing for maximal potassium excretion. This effectiveness of thiazide diuretics in pseudohypoaldosteronism has been observed by others [23, 29] . Patients should be warned not to allow themselves to become volume-contracted, as this condition will worsen potassium excretion by diminishing delivery of filtrate into the distal tubule, upon which potassium secretion depends. If these measures fail, sodium bicarbonate can be used orally to attempt to increase potassium excretion. Ion exchange resins (kayexalate) are a last step in the control of chronic, life-threatening hyperkalemia. Since starting hydrochlorothiazide, our patient has had no recurrence of his hyperkalemia, and his hypertension has been well controlled.
Chronic hyperkalemia poses a diagnostic and therapeutic challenge for the physician. After exclusion of the more common causes, a group of patients can be found whose hyperkalemia results from pseudohypoaldosteronism, a defect in renal excretion of potassium despite normal aldosterone production. Recognition of these patients is important therapeutically, since they fail to respond to exogenous mineralocorticoids, and treatment with thiazide diuretics often corrects their hyperkalemia and hypertension. In addition, family members should be screened for asymptomatic hyperkalemia. As more patients such as the one described in this paper are identified, their long-term clinical course, as well as the nature of their renal tubular defect, will become elucidated.
